25 E. Pearson
Chicago, IL 60611
United States
Loyola University of Chicago School of Law
SSRN RANKINGS
in Total Papers Downloads
in Total Papers Citations
patent, drug, pharmaceutical, innovation, cognitive bias, schema, drug development
patent, biopiracy, WTO, TRIPS, CBD
TRIPS, patent, compulsory license, Doha Public Health Declaration, paragraph 6, Article 31bis, TRIPS Council, Canada, Rwanda, Apotex
Patent, TRIPS, ACTA, Drug, Medicine, Compulsory License, Data Exclusivity, Patent Linkage
patent, compulsory license, TRIPS, drugs, pharmaceutials, Thailand, emergency
patent, TRIPS, pharmaceuticals, Thailand, compulsory license, middle-income, developing country
intellectual property, patent, investor-state arbitration, ISDS, investment arbitration, NAFTA, TRIPS, drug, pharmaceutical, public health, access to medicine,TPP, TTIP, CETA, expropriation, FET, fair and equitable treatment, clinical data
TRIPS, TRIPS-Plus, FTA, PCT, Pipeline, Access to medicine, data exclusivity, patent linkage, generic drug
IP, nationalism, COVID,TRIPS, global public goods, access to medicine, vaccine, drug, innovation, compulsory license, WTO, COVAX
patent, TRIPS, compulsory license, Thailand, middle-income
Tobacco, Regime Shifting, WTO, Plain Packaging, Investor-State Reform, TRIPS, Human Rights
TRIPS, WTO, patentability, patent rights, patent term, data protection
patents, access to medicine, Doha Public Health Declaration, PhRMA, South Africa, Brazil, TRIPS, TRIPS-Plus, A2K, WHO, WIPO
data exclusivity, patent linkage, generic drugs, Hatch-Waxman, PhARMA
patent, public health, TRIPS, TRIPS plus, compulsory license, A2K, WTO
Patent, TRIPS, India, Section 3d, New Use, New Forms of Known Substances, Prior Use, Opposition, Mailbox Application, International Exhaustion, Data Protection, Patent Linkage, Generic Drug
patent, patent reform, patentable subject matter, Supreme Court
teaching,formative, summative, assessment, test, statute, skills, Carnegie Report
patent, TRIPS, drug, pharmaceutical, India, Canada, promise doctrine, 3d
teaching, active learning, personal jurisdiction, PJ, assessment, feedback, pretesting, formative assessment, multiple assessment, multiple choice, MCQ
TRIPS, ISDS, investor-state, Eli Lilly, plain package tobacco, patent, trademark
Biosimilar, biologic, FDA, cognitive bias, misinformation, marketing, drug, Medicare, pharmacy substitution
patent, drug, drug prices, international exhaustion, parallel import, domestic exhaustion, first sale, gray market, price discrimination
Civil procedure, IRAC, law, exams,1L, formative assessment, online learning, collaboration
drug development, brand, generic, marketing patent data exclusivity
patent, TRIPS, pharmaceuticals, medicine, Thailand, compulsory license, social cognition
Commercial Speech, Sorrell, Caronia, FDA, Off-Label, Marketing, Pharmaceutical, Cognitive Bias, Schema
health policy, clinical trial transparency, WTO, TRIPS, trade secret, COVID-19, clinical data, drugs
ISDS, investor-state, plain package tobacco, TRIPS, expropriation, FET
patent, TRIPS, health, India, Thailand, compulsory license, Doha Public Health Declaration
IP, patent, ISDS, investor-state arbitration, TRIPS, NAFTA, expropriation, fair and equitable treatment, utility, industrial application, promise doctrine, secondary patents, evergreening
TRIPS flexibilities, ISDS, investor-state dispute, Eli Lilly, promise doctrine, tobacco label, Philip Morris
patent law, justice, progres of justice
Patent, Bayh-Dole, research, license, open-source
IP, Intellectual Property, COVID, pandemic, data exclusivity, patent linkage, TRIPS, FTA
patent, TRIPS, generic, drugs, in-transit, EU regulation
Bayh-Dole, Patents, Regulations, March-In, Pricing
WHO, COVID, pandemic treaty, pandemic agreement, IP, technology transfer, R&D, patent
Trade secret, IP, health, patent, fracking
artificial intelligence, intellectual property, patent law, copyright law, healthcare, biological sciences, medicine, medical device, deep learning, trade secrecy
IP, WHO, pandemic, national security, COVID, trade secret, global security, trade secret, patent, data exclusivity, pandemic agreement, TRIPS COVID waiver, public good, technology transfer, benefit sharing, TRIPS
